$ADXN News

Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript

Addex Therapeutics Q4 2025 Earnings Call Transcript

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex Therapeutics Q4 EPS $(1.50) Down From $(1.37) YoY, Sales $20.020K Up From $1.719K YoY

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Addex Therapeutics GABAB PAM Shows Reduced Cough Frequency And Lower Ashcroft Scores In Bleomycin IPF Model

Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Addex Unit Neurosterix Eyes Q2 2026 Completion Of NTX-253 Phase 1 Study, Evaluating Safety And Pharmacokinetics In Schizophrenia Patients

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex Therapeutics' Novel Gamma-Aminobutyric Acid Sub-Type B Receptor (GABAB) Positive Allosteric Modulator (PAM) Drug Candidate Demonstrates Baclofen-Like Efficacy In Non-Human Primate Chronic Cough Study

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Addex's Preclinical Data Published In Molecular Psychiatry Highlights mGlu7 Negative Allosteric Modulators As Promising Therapy For PTSD And Anxiety

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Backed Neurosterix Advances NTX-253 Into Phase 1 Clinical Trial For Schizophrenia Treatment

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Addex Therapeutics Amends At The Market Offering Agreement With H.C. Wainwright & Co. For ADSs Up To $3.3M

Addex Therapeutics Files Prospectus To Offer And Sell Ads For Up To $3.3M From Time To Time

Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst ...

Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update